Abnormal FHIT gene transcript and c-myc and c-erbB2 amplification in breast cancer.

• Authors: Renata Kowara , Filip Gołębiowski , Paweł Chrzan , Jaroslaw Skokowski , Andrzej Karmolinski , Tadeusz Pawełczyk
• Languages of publication: EN

Abstracts

EN

Searching for ways to improve the characterization of breast cancer we examined the relationship between the status of the FHIT gene transcript and amplification of c-myc and the c-erbB2 oncogene. Abnormal FHIT transcript was detected in 32 of 79 cancers examined. The presence of Fhit protein estimated by Western blots was evident only in cancers exhibiting a normal-sized FHIT transcript. This indicates that abnormal FHIT transcripts observed in our study did not encode any Fhit protein or the amount of such protein was very low. There was no association between the presence of aberrant FHIT gene transcript with age, tumor size, estrogen and progesterone receptor status, local metastases and histological grading. However, the abnormalities in FHIT gene transcripts were observed with different frequency depending on the histopathological type of the tumor. The aberrant FHIT transcript was detected in 60% of lobular cancers and only in 28% of ductal cancers. Analyzing the occurrence of c-myc and c-erbB2 amplification and the presence of aberrant FHIT gene transcripts we found that the aberrant FHIT transcript more frequently occurred in tissues with c-myc amplification. There was a significant (P <0.05) correlation between the occurrence of the aberrant FHIT gene transcript with accompanying c-myc amplification and positive lymph node status. However, in order to evaluate the predictive value of these findings in breast cancer, an extended clinical follow up will be necessary.

Keywords

EN

amplification; c-myc; FHIT transcripts; breast cancer; c-erbB2

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2002
• Volume: 49
• Issue: 2
• Pages: 341-350

Dates

published

2002

received

2001-11-13

revised

2002-05-21

accepted

2002-05-26

Contributors

author

Renata Kowara

• Department of Molecular Medicine, Medical University of Gdańsk, Gdańsk, Poland

author

Filip Gołębiowski

• Department of Molecular Medicine, Medical University of Gdańsk, Gdańsk, Poland

author

Paweł Chrzan

• Department of Molecular Medicine, Medical University of Gdańsk, Gdańsk, Poland

author

Jaroslaw Skokowski

• Department of Surgical Oncology, Medical University of Gdańsk, Gdańsk, Poland

author

Andrzej Karmolinski

• Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland

author

Tadeusz Pawełczyk

• Medical Research Center of the Polish Academy of Sciences, Warszawa, Poland

References

• Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD, Gazdar AF. (1997) Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res.; 57: 3664-8.
• Baffia R, Veronese ML, Santoro B, Mandes B, Palazzo JP, Rugge M, Santoro E, Croce CM, Huebner K. (1998) Laoo os FIHT expression in gastric carcinoma.Cancer Res; 58: 4708-14.
• Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. (1996) Fhit, a putative tumor suppressor in humans is a dinucleoside 5',5''-P1,P3-triphosphate hydrolase. Biochemistry.; 35: 11529-35.
• Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. (1992) Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumors: correlation with steroid receptors. Eur J Cancer.; 28: 697-700.
• Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG. (1995) Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene.; 159: 11-8.
• Bloom HJ, Richardson WW. (1957) Histological grading and prognosis in breast cancer. Br J Cancer.; 11: 359-77.
• Borg A, Baldetrop B, Ferno M, Olsson H, Sigurdsson H. (1992) c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer.; 51: 687-91.
• Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. (1999) FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res.; 59: 3866-9.
• Champeme MH, Bieche I, Hacene K, Lidereau R. (1994) Oncogene amplification per se: an independent prognostic factor in human breast cancer. Mol Carcinog.; 11: 189-91.
• Chen Y, Dong J, Lu Y, McGee JO. (1995) Quantitative detection of amplification of proto-oncogenes in breast cancer. Chin Med J.; 108: 849-54.
• Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T. (2001) Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin Biochem.; 34: 557-62.
• Deming SL, Nass SJ, Dickson RB, Trock BJ. (2000) c-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer.; 83: 1688-95.
• Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K. (1997) Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res.; 57: 504-12.
• Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. (1997) FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res.; 57: 2256-67.
• Guo Z, Johansson SL, Rhim JS, Vishwanatha JK. (2000) Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. Prostate.; 43: 101-10.
• Hayashi S, Tanimoto K, Hajiro-Nakanishi K, Tsuchiya E, Kurosumi M, Hagashi Y, Imai K, Suga K, Nakachi K. (1997) Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res.; 57: 1981-5.
• Huiping C, Jonasson JG, Agnarsson BA, Sigbjornsdottir BI, Huebner K, Ingvarsson S. (2000) Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer. Eur J Cancer.; 36: 1552-7.
• Ingvarson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA. (2001) Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prev.; 25: 292-8.
• Lonn U, Lonn S, Nilsson B, Stenkvist B. (1995) Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer.; 75: 2681-7.
• Mark HF, Aswad B, Bassily N, Taylor W, Brown S, Sun CL, Samy M, Zolnierz K, Wong E, Bland KI, Hsu PH. (1999) HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization. Genet Med.; 1(3): 98-103.
• Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. (1996) The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res.; 56: 3173-9.
• Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell.;84: 587-97.
• Otterson GA, Xiao G-H, Geradts J, Jin F, Chen W, Niklinska W, Kaye FJ, Yeung RS. (1998) Protein expression and functional analysis of the FHIT gene in human tumor cells. J Natl Cancer Inst.; 90: 426-32.
• Pandis N, Bardi G, Mitelman F, Heim S. (1997) Deletion of the short arm of chromosome 3 in breast tumors. Genes Chromosomes Cancer.; 18: 241-5.
• Sakowicz M, Grden M, Pawelczyk T. (2001) Expression level of adenosine kinase in rat tissues. Lack of phosphate effect on the enzyme activity. Acta Biochim Polon.; 48: 745-55.
• Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. (1997) Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A.; 94: 13771-6.
• Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minolitti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, Croce CM, Pierotti MA. (1997) Absence of Fhit protein in primary lung tumors and cells lines with FHIT gene abnormalities. Cancer Res.; 57: 5207-12.
• Watson PH, Safneck JR, Le K, Dubik D, Shiu RP. (1993) Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst.; 85: 902-7.
• Yoshino K, Enomoto T, Nakamura T, Sun H, Ozaki K, Nakashima R, Wanada H, Saitoh J, Watanabe Y, Noda K, Murata Y. (2000) FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer.; 85: 6-13.
• Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. (2000) Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res.; 60: 1049-53.
• Zou TT, Lei J, Shi YQ, Yin J, Wang S, Souza RF, Kong D, Shimada Y, Smolinski KN, Greenwald BD, Abraham JM, Harpaz N, Meltzer SJ. (1997) FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Oncogene.; 15: 101-15.
• Zou M, Shi Y, Farid NR, al-Sedairy ST, Paterson MC. (1999) FHIT gene abnormalities in both benign and malignant thyroid tumors. Eur J Cancer.; 35: 467-72.